10-Q: INmune Bio Q2 Loss Widens on XPro Impairment, CEO Resigns

INmune Bio Inc. reported a widened net loss for Q2 2025, primarily due to a $16.5 million impairment charge related to its Alzheimer's drug candidate, XPro, following mixed Phase 2 results, alongside a CEO transition and ongoing liquidity concerns.

Summary

• Net loss for the six months ended June 30, 2025, increased significantly to $34.2 million, up from $20.8 million in the prior year.
• An impairment charge of $16.5 million was recorded for acquired in-process research and development intangible assets related to the Alzheimer's drug candidate, XPro, after its Phase 2 trial failed to meet primary endpoints.
• Despite the primary endpoint failure, a prespecified subgroup analysis of XPro showed trends toward improvement in cognitive and neuropsychiatric symptoms, with the company seeking a partner for further development.
• The company faces substantial doubt about its ability to continue as a going concern, projecting insufficient liquidity to sustain operations for the next year.
• Progress was noted in the CORDStrom program for Recessive Dystrophic Epidermolysis Bullosa (RDEB), with positive Phase 2 results, Rare Pediatric Disease Designation (RPDD), and Orphan Drug Designation (ODD) from the FDA, with BLA submission planned for this year.
• The INKmune program for metastatic castrate resistant prostate cancer is in Phase II, with full enrollment estimated by Q4 2025 and top-line data 6 months later.
• Dr. Raymond J. Tesi resigned as President, CEO, CMO, and Chairman, effective August 12, 2025, with David J. Moss appointed as the new President and CEO, and Cory Ellspermann as Interim CFO.

Sentiment

Score: 3

Explanation: The significant increase in net loss, the substantial impairment charge on a key asset (XPro) due to trial failure, and the explicit 'going concern' warning present considerable risks and negative financial indicators. While there are promising signals in other programs and successful recent capital raises, the immediate financial instability and the setback in the lead Alzheimer's program create a highly negative overall sentiment for the company's near-term prospects.

Positives

• CORDStrom Phase 2 trial showed beneficial effects in pediatric RDEB patients, including significant reduction in itch scores and improved skin integrity.
• CORDStrom received Rare Pediatric Disease Designation (RPDD) from the FDA on December 13, 2024, making it eligible for a Priority Review Voucher upon approval.
• CORDStrom received Orphan Drug Designation (ODD) from the FDA on January 6, 2025, providing benefits like tax credits, grant eligibility, fee waivers, and 7 years of market exclusivity.
• The company plans to submit a Biologics License Application (BLA) for CORDStrom this year and Marketing Authorization Applications (MAAs) to the EU and UK in 2026.
• XPro's Phase 2 trial, despite missing primary endpoints, showed a "promising signal" in a prespecified subgroup of Alzheimer's patients with higher inflammation, with an effect size of 0.27 on EMACC.
• Successful capital raises in Q2 2025, including $17.4 million net from a registered direct offering and $10.1 million net from an At-The-Market (ATM) program, significantly increased cash and cash equivalents to $33.4 million.
• Research and development tax credits from Australia and the United Kingdom continue to reduce R&D expenses.

Negatives

• Net loss for the six months ended June 30, 2025, significantly increased to $34.2 million, compared to $20.8 million for the same period in 2024.
• A $16.5 million impairment charge was recorded on acquired in-process research and development intangible assets due to XPro's Phase 2 trial failing to meet its primary endpoint and insufficient resources to fund further trials.
• The company projects insufficient liquidity to sustain operations through one year following the financial statements' issuance, raising substantial doubt about its ability to continue as a going concern.
• Immediate plans to develop XPro for Alzheimer's or other indications have been halted, with the company now seeking a partner for further studies.
• The Phase 1 trial for INKmune in high-risk MDS/AML was terminated in March 2024 due to post-Covid recruitment problems.
• The second part of the MissionEB study for CORDStrom is currently uninitiated due to a lack of funding by the National Health Services England (NHSE).

Risks

• Substantial doubt about the ability to continue as a going concern due to significant losses and negative cash flows.
• Inability to secure additional financing on favorable terms, which could lead to delays, scaling back, or discontinuation of product candidates or cessation of operations.
• Dilution to existing stockholders if additional funds are raised through equity sales.
• Uncertainty regarding the successful completion of research and development, intellectual property protection, regulatory approval, and commercial viability of product candidates.
• Dependence on a small number of vendors for manufacturing supplies and materials, posing a risk of significant interruption.
• Fluctuations in foreign currency exchange rates (USD vs. GBP and AUD) could adversely affect financial results.
• Clinical trials are costly, time-consuming, and highly uncertain, with no assurance of success or commercial availability for several years, if ever.

Future Outlook

The company plans an end-of-phase 2 meeting with the FDA for XPro towards the end of 2025 to determine next steps, expecting eligibility for Breakthrough status. For CORDStrom, the company intends to prepare for and hold a pre-BLA meeting with the FDA, with the goal of submitting a Biologics License Application (BLA) this year for RDEB treatment, and concurrently submitting Marketing Authorization Applications (MAAs) to the EU and UK in 2026. The INKmune Phase I/II trial for metastatic castrate resistant prostate cancer is estimated to be fully enrolled by Q4 2025, with top-line data expected six months thereafter.

Management Comments

• "The findings from the Phase 2 results indicate that XPro may offer benefits to a readily identified subgroup of Alzheimer's patients across all ages with biomarker-defined neuroinflammation, regardless of comorbidities or ApoE4 status and potentially lays the foundation for advancing XPro as a promising treatment for AD."
• "CORDStrom products are designed to provide high-quality, off-the-shelf, batch-to-batch consistent, scalable, cGMP manufactured, potent cellular medicines that can be produced at low cost and with repeatable specification."
• "INKmune improves the ability of the patients own NK cells to attack their tumor, converting inert resting NK cells into memory-like NK cells that kill the patients cancer cells."
• "Our recurring net losses and negative cash flows from operations raised substantial doubt regarding our ability to continue as a going concern within one year after the issuance of our unaudited condensed consolidated financial statements."

Industry Context

INmune Bio operates in the clinical-stage biotechnology sector, focusing on developing therapies that modulate the innate immune system for diseases like Alzheimer's, rare pediatric conditions (RDEB), and various cancers. The company's precision medicine approach, targeting specific immune dysfunctions, aligns with broader industry trends towards personalized and targeted therapies. The significant impairment charge on its Alzheimer's asset highlights the inherent high-risk, high-reward nature of drug development, particularly in complex neurological diseases where clinical trial outcomes are highly uncertain. The progress in CORDStrom for RDEB, an orphan disease, reflects a growing industry focus on unmet medical needs and the potential for expedited regulatory pathways (RPDD, ODD) in these areas. The company's financial challenges and reliance on external funding are common for clinical-stage biotechs that have not yet commercialized products.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark against global industry standards.
• The Phase 2 trial design for XPro, requiring a decline in the placebo group to demonstrate efficacy, is a standard approach in Alzheimer's clinical trials. The lack of decline in the overall placebo group, while problematic for the primary endpoint, is not uncommon in AD trials, which often face challenges in demonstrating statistically significant cognitive benefits over short durations.
• The use of effect size (Cohen's D) for subgroup analysis (0.27 for EMACC) is a recognized method for signal detection in Phase 2 studies, indicating potential clinical relevance even without statistical significance (p-value 0.16).
• The safety profile of CORDStrom, being "easily administered, well tolerated and no CORDStrom related serious adverse events," is a positive indicator, aligning with desirable safety standards for new therapies, especially in pediatric populations.
• The receipt of Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) for CORDStrom is consistent with industry efforts to accelerate development for rare diseases with high unmet needs, offering significant regulatory and financial incentives.

Management Changes

Corporate Governance

Legal Proceedings

• Ongoing dispute with a vendor regarding approximately $1.6 million in invoices, of which the company has recorded $0.2 million and disputes the remaining $1.4 million, believing them to be erroneous. Legal proceedings have not been threatened.

Related Party Transactions

• Immune Ventures, LLC (owned by former CEO Raymond J. Tesi, new CEO David Moss, and CSO Mark Lowdell) is the licensor for the INKmune License Agreement, with $25,000 payable as of June 30, 2025, for a Phase I initiation milestone.
• The University of Pittsburgh is owed $25,000 for annual maintenance fees under the PITT Agreement as of June 30, 2025, for intellectual property assigned from Immune Ventures.
• UCL (University of London subsidiary, where the company's Chief Scientific and Manufacturing Officer is a professor) is owed $133,000 as of June 30, 2025, for medical research performed.
• AmplifyBio (whose former CEO is on the company's board of directors) was owed $26,000 as of June 30, 2025, for medical research performed, though AmplifyBio ceased operations in 2025.

Stakeholder Impact

• Shareholders face significant dilution risk from future equity raises, potential negative impact on share price due to increased net loss, XPro impairment, and going concern warning. However, successful capital raises provide short-term liquidity.
• Employees may experience impacts from significant management changes at the top (CEO, CFO, Chairman) which could affect morale and strategic direction.
• Patients: Development of XPro for Alzheimer's is halted (seeking partner), potentially delaying access to a treatment that showed some subgroup benefit. CORDStrom for RDEB shows promising results and is moving towards BLA submission, offering hope for patients with a severe orphan disease. INKmune continues in prostate cancer trials.
• Creditors: The "going concern" warning indicates increased risk for creditors, though the company recently paid off a term loan.
• Suppliers/Vendors: An ongoing dispute with a vendor over $1.4 million in invoices could strain relationships.

Next Steps

• Plan an end-of-phase 2 meeting with the FDA for XPro towards the end of 2025 to determine next steps and discuss Breakthrough status eligibility.
• Seek a partner to continue XPro studies for Alzheimer's or other indications due to insufficient internal resources.
• Prepare for and hold a pre-BLA meeting with the FDA for CORDStrom.
• Submit a Biologics License Application (BLA) for CORDStrom for RDEB treatment this year.
• Submit Marketing Authorization Applications (MAAs) for CORDStrom to the EU and United Kingdom in 2026.
• Continue Phase II enrollment for the INKmune trial in metastatic castrate resistant prostate cancer, with full enrollment estimated by Q4 2025 and top-line data 6 months later.
• Pursue an open-label study for CORDStrom for patients who completed the Mission EB study and wish to continue therapy.
• Revisit the terms of employment for the new President and CEO, David J. Moss, and the Interim CFO, Cory Ellspermann, by the Compensation Committee and the Board.

Key Dates

Recommendation

While the significant net loss, the substantial impairment charge on the XPro Alzheimer's program, and the explicit 'going concern' warning present considerable risks and negative financial indicators, the company has demonstrated progress in other key areas. The CORDStrom program for RDEB shows promising clinical results and has secured important regulatory designations (RPDD, ODD), positioning it for a BLA submission this year. The INKmune oncology program is also advancing. The recent capital raises have provided a temporary liquidity buffer. Given the mixed bag of a major setback in one program balanced by promising developments in others and a recent cash infusion, a 'hold' recommendation is appropriate. Investors should monitor the company's ability to secure a partner for XPro, progress with CORDStrom's regulatory pathway, and its ongoing efforts to address the going concern issue through further financing or strategic collaborations. The stock remains highly speculative due to its clinical-stage nature and financial challenges.

Keywords

Biotechnology, Biopharmaceutical, Clinical Stage, Alzheimer's Disease, Recessive Dystrophic Epidermolysis Bullosa, RDEB, Cancer, Oncology, Innate Immune System, Neuroinflammation, DN-TNF, XPro1595, CORDStrom, INKmune, SEC Filing, 10-Q, Financial Results, Drug Development, Orphan Drug, Rare Pediatric Disease, Going Concern, Management Change